Table of Content

1. Key Insights

2. Executive Summary of Essential Thrombocythemia (ET)

3. Essential Thrombocythemia (ET): Market Overview at a Glance
3.1. Total Market Share (%) Distribution of ET in 2017
3.2. Total Market Share (%) Distribution of ET in 2030

4. Disease Background and Overview: Essential Thrombocythemia (ET)
4.1. Introduction
4.2. Symptoms
4.3. Causes
4.4. Risk Factors
4.5. Pathogenesis
4.6. Diagnosis of ET
4.6.1. 2016 World Health Organization Diagnostic Criteria for Essential Thrombocythemia
4.6.2. Diagnostic criteria of essential thrombocythemia by the British Committee for Standards in Haematology
4.6.3. International Prognostic Score for Thrombosis in Essential Thrombocythemia
4.6.4. Diagnostic algorithm

5. Case Reports
5.1. A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge
5.2. Case Report: Headache in a Postpartum Patient with Essential Thrombocytosis
5.3. Essential Thrombocythemia in a young man treated for myocardial infarction
5.4. Next-generation sequencing redefines a triple-negative Essential Thrombocythemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots
5.5. JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Essential Thrombocythemia (ET) in the United States
7.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the United States
7.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in the United States
7.5. Age-specific Diagnosed Prevalence of ET in the United States
7.6. Prevalence of ET Cases Based on Risk in the United States
7.7. Gene Mutation specific Prevalence of ET in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Germany
8.1.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany
8.1.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Germany
8.1.5. Age-specific Diagnosed Prevalence of ET in Germany
8.1.6. Prevalence of ET Cases Based on Risk in Germany
8.1.7. Gene Mutation specific Prevalence of ET in Germany
8.2. France Epidemiology
8.2.1. Assumptions and rationale
8.2.2. Total Prevalent Population of Essential Thrombocythemia (ET) in France
8.2.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France
8.2.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in France
8.2.5. Age-specific Diagnosed Prevalence of ET in France
8.2.6. Prevalence of ET Cases Based on Risk in France
8.2.7. Gene Mutation specific Prevalence of ET in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Italy
8.3.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy
8.3.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Italy
8.3.5. Age-specific Diagnosed Prevalence of ET in Italy
8.3.6. Prevalence of ET Cases Based on Risk in Italy
8.3.7. Gene Mutation specific Prevalence of ET in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Spain
8.4.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain
8.4.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Spain
8.4.5. Age-specific Diagnosed Prevalence of ET in Spain
8.4.6. Prevalence of ET Cases Based on Risk in Spain
8.4.7. Gene Mutation specific Prevalence of ET in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Prevalent Population of Essential Thrombocythemia (ET) in the UK
8.5.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK
8.5.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in the UK
8.5.5. Age-specific Diagnosed Prevalence of ET in the UK
8.5.6. Prevalence of ET Cases Based on Risk in the UK
8.5.7. Gene Mutation specific Prevalence of ET in the UK

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Prevalent Population of Essential Thrombocythemia (ET) Japan
9.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan
9.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Japan
9.5. Age-specific Diagnosed Prevalence of ET in Japan
9.6. Prevalence of ET Cases Based on Risk in Japan
9.7. Gene Mutation specific Prevalence of ET in Japan

10. Current Treatment and Medical Practices
10.1. Risk categories of patients with ET
10.2. Treatment of Essential Thrombocythemia (ET)
10.3. Treatment Algorithm
10.4. Treatment Guidelines
10.4.1. National Comprehensive Cancer Network Guidelines
10.4.2. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
10.4.3. UCLP Myeloproliferative Neoplasms Group: Essential Thrombocythaemia Guideline
10.4.4. The Japanese Society of Hematology guidelines for the treatment of Essential Thrombocythaemia

11. Unmet Needs

12. Marketed Drugs
12.1. Agrylin/Xagrid: Shire
12.1.1. Product Description
12.1.2. Regulatory Milestones
12.1.3. Safety and Efficacy
12.1.4. Product Profile
12.2. Thromboreductin: AOP Orphan Pharmaceuticals
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Safety and Efficacy
12.2.4. Product Profile

13. Emerging Therapies
13.1. Ropeginterferon alfa-2b (P1101): PharmaEssentia
13.1.1. Product Description
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Product Profile
13.2. Jakavi (ruxolitinib): Novartis
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Bomedemstat (IMG-7289): Imago BioSciences
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Safety and Efficacy
13.3.5. Product Profile
13.4. Gandotinib (LY2784544): Eli Lilly and Company
13.4.1. Product Description
13.4.2. Clinical Development
13.4.3. Safety and Efficacy
13.4.4. Product Profile
13.5. Imetelstat: Geron Corporation
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.4. Safety and Efficacy
13.5.5. Product Profile
13.6. Givinostat (ITF2357): Italfarmaco
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Safety and Efficacy
13.6.5. Product Profile
13.7. Anagrelide Controlled Release/GALE-401: Galena Biopharma
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Safety and Efficacy
13.7.5. Product Profile
14. Essential Thrombocythemia (ET): 7MM Market Analysis
14.1. Key Findings
14.2. Market Size of Essential Thrombocythemia (ET) in the 7MM
14.3. Market Size of Essential Thrombocythemia (ET) by Therapies in the 7MM
15. United States
15.1. United States: Market Outlook
15.2. United States Market Size
15.2.1. Total Market size of Essential Thrombocythemia (ET) in the US
15.2.2. Market Size of Essential Thrombocythemia (ET) by Therapies in the US
16. EU-5 countries
16.1. EU-5 Market Outlook
16.2. Germany Market Size
16.2.1. Total Market size of Essential Thrombocythemia (ET) in Germany
16.2.2. Market Size of Essential Thrombocythemia (ET) by therapies in Germany
16.3. France Market Size
16.3.1. Total Market size of Essential Thrombocythemia (ET) in France
16.3.2. Market Size of Essential Thrombocythemia (ET) by therapies in France
16.4. Italy Market Size
16.4.1. Total Market size of Essential Thrombocythemia (ET) in Italy
16.4.2. Market Size of Essential Thrombocythemia (ET) by therapies in Italy
16.5. Spain Market Size
16.5.1. Total Market size of Essential Thrombocythemia (ET) in Spain
16.5.2. Market Size of Essential Thrombocythemia (ET) by therapies in Spain
16.6. United Kingdom Market Size
16.6.1. Total Market size of Essential Thrombocythemia (ET) in the United Kingdom
16.6.2. Market Size of Essential Thrombocythemia (ET) by therapies in the UK

17. Japan
17.1. Market Outlook
17.2. Japan Market Size
17.2.1. Total Market size of Essential Thrombocythemia (ET) in Japan
17.2.2. Market Size of Essential Thrombocythemia (ET) by therapies in Japan

18. Market Drivers

19. Market Barriers

20. Reimbursement and Market Access
21. SWOT Analysis
22. KOL Views
23. Appendix
24. Bibliography
24.1. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight



List of Figures


Figure 1 Laboratory Features of Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis
Figure 2 Common symptoms of ET
Figure 3 Gene mutations in ET
Figure 4 Role of JAK2 in pathway signaling and erythropoietin binding, stem-cell differentiation, and development of homozygosity for the V617F mutation
Figure 5 Diagnostic algorithm for essential thrombocythemia
Figure 6 Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM (2017–2030)
Figure 7 Total Prevalent Population of Essential Thrombocythemia (ET) in the US (2017–2030)
Figure 8 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the US (2017–2030)
Figure 9 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the US (2017–2030)
Figure 10 Age-specific Diagnosed Prevalence of ET in the US (2017–2030)
Figure 11 Prevalence of ET Based on Risk in the US (2017–2030)
Figure 12 Gene Mutation specific Prevalence of ET in the US (2017–2030)
Figure 13 Total Prevalent Population of Essential Thrombocythemia (ET) in Germany (2017–2030)
Figure 14 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany (2017–2030)
Figure 15 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Germany (2017–2030)
Figure 16 Age-specific Diagnosed Prevalence of ET in Germany (2017–2030)
Figure 17 Prevalence of ET Based on Risk in Germany (2017–2030)
Figure 18 Gene Mutation specific Prevalence of ET in Germany (2017–2030)
Figure 19 Total Prevalent Population of Essential Thrombocythemia (ET) in France (2017–2030)
Figure 20 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France (2017–2030)
Figure 21 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in France (2017–2030)
Figure 22 Age-specific Diagnosed Prevalence of ET in France (2017–2030)
Figure 23 Prevalence of ET Based on Risk in France (2017–2030)
Figure 24 Gene Mutation specific Prevalence of ET in France (2017–2030)
Figure 25 Total Prevalent Population of Essential Thrombocythemia (ET) in Italy (2017–2030)
Figure 26 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy (2017–2030)
Figure 27 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Italy (2017–2030)
Figure 28 Age-specific Diagnosed Prevalence of ET in Italy (2017–2030)
Figure 29 Prevalence of ET Based on Risk in Italy (2017–2030)
Figure 30 Gene Mutation specific Prevalence of ET in Italy (2017–2030)
Figure 31 Total Prevalent Population of Essential Thrombocythemia (ET) in Spain (2017–2030)
Figure 32 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain (2017–2030)
Figure 33 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Spain (2017–2030)
Figure 34 Age-specific Diagnosed Prevalence of ET in Spain (2017–2030)
Figure 35 Prevalence of ET Based on Risk in Spain (2017–2030)
Figure 36 Gene Mutation specific Prevalence of ET in Spain (2017–2030)
Figure 37 Total Prevalent Population of Essential Thrombocythemia (ET) in the UK (2017–2030)
Figure 38 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK (2017–2030)
Figure 39 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the UK (2017–2030)
Figure 40 Age-specific Diagnosed Prevalence of ET in the UK (2017–2030)
Figure 41 Prevalence of ET Based on Risk in the UK (2017–2030)
Figure 42 Gene Mutation specific Prevalence of ET in the UK (2017–2030)
Figure 43 Total Prevalent Population of Essential Thrombocythemia (ET) in Japan (2017–2030)
Figure 44 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan (2017–2030)
Figure 45 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Japan (2017–2030)
Figure 46 Age-specific Diagnosed Prevalence of ET in Japan (2017–2030)
Figure 47 Prevalence of ET Based on Risk in Japan (2017–2030)
Figure 48 Gene Mutation specific Prevalence of ET in Japan (2017–2030)
Figure 49 Current treatment algorithm in essential thrombocythemia
Figure 50 Unmet Needs of Essential Thrombocythemia (ET)
Figure 51 Market Size of Essential Thrombocythemia (ET) in the 7MM in USD Million (2017–2030)
Figure 52 Market Size of Essential Thrombocythemia (ET) by therapies in the 7MM, in USD Million (2017–2030)
Figure 53 Market Size of Essential Thrombocythemia (ET) in the US, USD Millions (2017–2030)
Figure 54 Market Size of Essential Thrombocythemia (ET) by therapies in the US, in USD Million (2017–2030)
Figure 55 Market Size of Essential Thrombocythemia (ET) in Germany, USD Millions (2017–2030)
Figure 56 Market Size of Essential Thrombocythemia (ET) by therapies in Germany, in USD Million (2017–2030)
Figure 57 Market Size of Essential Thrombocythemia (ET) in France, USD Millions (2017–2030)
Figure 58 Market Size of Essential Thrombocythemia (ET) by therapies in France, in USD Million (2017–2030)
Figure 59 Market Size of Essential Thrombocythemia (ET) in Italy, USD Millions (2017–2030)
Figure 60 Market Size of Essential Thrombocythemia (ET) by therapies in Italy in USD Million (2017–2030)
Figure 61 Market Size of Essential Thrombocythemia (ET) in Spain, USD Millions (2017–2030)
Figure 62 Market Size of Essential Thrombocythemia (ET) by therapies in Spain in USD Million (2017–2030)
Figure 63 Market Size of Essential Thrombocythemia (ET) in the UK, USD Millions (2017–2030)
Figure 64 Market Size of Essential Thrombocythemia (ET) by therapies in the UK in USD Million (2017–2030)
Figure 65 Market Size of Essential Thrombocythemia (ET) in Japan, USD Millions (2017–2030)
Figure 66 Market Size of Essential Thrombocythemia (ET) by therapies in Japan in USD Million (2017–2030)
Figure 67 Market Drivers
Figure 68 Market Barriers
Figure 69 SWOT analysis of Essential Thrombocythemia
Figure 70 United States KOL Views
Figure 71 EU KOL Views
Figure 72 Japan KOL Views


List of Tables


Table 1 Summary of Essential Thrombocythemia (ET), Market, Epidemiology and Key Events (2017–2030)
Table 2 Distribution of mutation in ET patients
Table 3 WHO criteria for the diagnosis of ET
Table 4 Proposed diagnostic criteria for essential thrombocythemia
Table 5 Significant risk factors for thrombosis in patients with WHO-defined ET and associated prognostic scores
Table 6 Risk group and prognosis
Table 7 Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM (2017–2030)
Table 8 Total Prevalent Population of Essential Thrombocythemia (ET) in the US (2017–2030)
Table 9 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the US (2017–2030)
Table 10 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the US (2017–2030)
Table 11 Age-specific Diagnosed Prevalence of ET in the US (2017–2030)
Table 12 Prevalence of ET Based on Risk in the US (2017–2030)
Table 13 Gene Mutation specific Prevalence of ET in the US (2017–2030)
Table 14 Total Prevalent Population of Essential Thrombocythemia (ET) in Germany (2017–2030)
Table 15 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany (2017–2030)
Table 16 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Germany (2017–2030)
Table 17 Age-specific Diagnosed Prevalence of ET in Germany (2017–2030)
Table 18 Prevalence of ET Based on Risk in Germany (2017–2030)
Table 19 Gene Mutation specific Prevalence of ET in Germany (2017–2030)
Table 20 Total Prevalent Population of Essential Thrombocythemia (ET) in France (2017–2030)
Table 21 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France (2017–2030)
Table 22 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in France (2017–2030)
Table 23 Age-specific Diagnosed Prevalence of ET in France (2017–2030)
Table 24 Prevalence of ET Based on Risk in France (2017–2030)
Table 25 Gene Mutation specific Prevalence of ET in France (2017–2030)
Table 26 Total Prevalent Population of Essential Thrombocythemia (ET) in Italy (2017–2030)
Table 27 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy (2017–2030)
Table 28 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Italy (2017–2030)
Table 29 Age-specific Diagnosed Prevalence of ET in Italy (2017–2030)
Table 30 Prevalence of ET Based on Risk in Italy (2017–2030)
Table 31 Gene Mutation specific Prevalence of ET in Italy (2017–2030)
Table 32 Total Prevalent Population of Essential Thrombocythemia (ET) in Spain (2017–2030)
Table 33 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain (2017–2030)
Table 34 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Spain (2017–2030)
Table 35 Age-specific Diagnosed Prevalence of ET in Spain (2017–2030)
Table 36 Prevalence of ET Based on Risk in Spain (2017–2030)
Table 37 Gene Mutation specific Prevalence of ET in Spain (2017–2030)
Table 38 Total Prevalent Population of Essential Thrombocythemia (ET) in the UK (2017–2030)
Table 39 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK (2017–2030)
Table 40 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the UK (2017–2030)
Table 41 Age-specific Diagnosed Prevalence of ET in the UK (2017–2030)
Table 42 Prevalence of ET Based on Risk in the UK (2017–2030)
Table 43 Gene Mutation specific Prevalence of ET in the UK (2017–2030)
Table 44 Total Prevalent Population of Essential Thrombocythemia (ET) in Japan (2017–2030)
Table 45 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan (2017–2030)
Table 46 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Japan (2017–2030)
Table 47 Age-specific Diagnosed Prevalence of ET in Japan (2017–2030)
Table 48 Prevalence of ET Based on Risk in Japan (2017–2030)
Table 49 Gene Mutation specific Prevalence of ET in Japan (2017–2030)
Table 50 NCCN treatment guidelines for ET
Table 51 Ropeginterferon alfa-2b, Clinical Trial Description, 2020
Table 52 Ruxolitinib, Clinical Trial Description, 2020
Table 53 IMG-7289, Clinical Trial Description, 2020
Table 54 LY2784544, Clinical Trial Description, 2020
Table 55 Imetelstat, Clinical Trial Description, 2020
Table 56 Givinostat (ITF2357), Clinical Trial Description, 2020
Table 57 Anagrelide CR, Clinical Trial Description, 2020
Table 58 Market Size of Essential Thrombocythemia (ET) in the 7MM in USD Million (2017–2030)
Table 59 Market Size of Essential Thrombocythemia (ET) by therapies in the 7MM, in USD Million (2017–2030)
Table 60 The US Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)
Table 61 Market Size of Essential Thrombocythemia (ET) by therapies in the US, in USD Million (2017–2030)
Table 62 Germany Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)
Table 63 Market Size of Essential Thrombocythemia (ET) by therapies in Germany, in USD Million (2017–2030)
Table 64 France Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)
Table 65 Market Size of Essential Thrombocythemia (ET) by therapies in France, in USD Million (2017–2030)
Table 66 Italy Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)
Table 67 Market Size of Essential Thrombocythemia (ET) by therapies in Italy, in USD Million (2017–2030)
Table 68 Spain Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)
Table 69 Market Size of Essential Thrombocythemia (ET) by therapies in Spain, in USD Million (2017–2030)
Table 70 The UK Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)
Table 71 Market Size of Essential Thrombocythemia (ET) by therapies in the UK, in USD Million (2017–2030)
Table 72 Japan Market Size of Essential Thrombocythemia (ET) in USD Million (2017–2030)
Table 73 Market Size of Essential Thrombocythemia (ET) by therapies in Japan, in USD Million (2017–2030)